Key statistics
As of last trade Myriad Genetics Inc (MYD:FRA) traded at 16.20, 5.88% above its 52-week low of 15.30, set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.20 |
---|---|
High | 16.20 |
Low | 16.20 |
Bid | 16.20 |
Offer | 16.60 |
Previous close | 16.30 |
Average volume | 143.43 |
---|---|
Shares outstanding | 90.82m |
Free float | 88.98m |
P/E (TTM) | -- |
Market cap | 1.58bn USD |
EPS (TTM) | -1.80 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 07:28 GMT.
More ▼
Announcements
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
- Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
- Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
- Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
- Myriad Genetics to Host Investor Event on October 9, 2024
More ▼